1 Correction to: PharmacoEconomics Open https://doi.org/10.1007/s41669-022-00339-1

In this article References 20–32 were numbered incorrectly.

Reference 32. in the original article should have been Reference 20. All subsequent references in the original article beginning from 20 should have moved one spot further.

The correct list of references is as follows:


References

  1. 1.

    NCCN Guidelines Version 3.2020. B-cell Lymphomas. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 5 Dec 2019.

  2. 2.

    Tilly H, Gomes da Silva M, Vitolo U, et al. ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol. 2015;26 (Suppl 5): v116–25

  3. 3.

    Morrison VA, Shou Y, Bell JA, et al. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol. 2019; 15: 1021–34.

  4. 4.

    Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer. 2014; 3: 66–70.

  5. 5.

    Mehta-Shah N, Bartlett NL. Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. Blood. 2018; 131 (15): 1698–703.

  6. 6.

    Kite Pharma, Inc., 2017. YESCARTA® (axicabtagene ciloleucel) suspension for intravenous infusion. Available at: https://www.gilead.com/-/media/files/pdfs/medicines/oncology/yescarta/yescarta-pi.pdf. Accessed 26 Sep 2019.

  7. 7.

    Kite Pharma EU B.V. YESCARTA Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/yescarta-epar-product-information_en.pdf. Accessed 26 Sep 2019.

  8. 8.

    Novartis, 2018. KYMRIAH™ (tisagenlecleucel) suspension for intravenous infusion. https://www.pharma.us.novartis.com/sites/. www.pharma.us.novartis.com/files/kymriah.pdf. Accessed 26 Sep 2019.

  9. 9.

    Novartis, 2018. Kymriah Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/kymriah-epar-product-information_en.pdf. Accessed 26 Sep 2019.

  10. 10.

    Genentech, Inc., 2019. POLIVY™ (polatuzumab vedotin) Summary of Product Characteristics. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf. Accessed 12 Sept 2019.

  11. 11.

    Genentech, Inc., 2020. POLIVY™ (polatuzumab vedotin) Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/polivy-epar-product-information_en.pdf. Accessed 21 Aug 2020.

  12. 12.

    Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for cured patients in cost-effectiveness analysis. Value Health. 2017; 20: 705–9.

  13. 13.

    Çağlayan Ç, Goldstein JS, Ayer T, et al. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients. Cancer. 2019; 125 (11): 1837–47.

  14. 14.

    Bansal A, Sullivan SD, Lin VW, et al. Estimating long-term survival for patients with relapsed or refractory large b-cell lymphoma treated with chimeric antigen receptor therapy: a comparison of standard and mixture cure rate models. Med Decis Making. 2019; 39: 294–8.

  15. 15.

    Lambert PC, Thompson JR, Weston CL, Dickman PW. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics. 2007; 8: 576–94.

  16. 16.

    Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma. J Clin Oncol. 2018; 36 (35): 3441–9.

  17. 17.

    Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020; 38 (2): 155–65.

  18. 18.

    The Human Mortality Database. www.mortality.org. Accessed 12 Sep 2019.

  19. 19.

    Latimer, N. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongsidelymphoma in the USA. Future Oncol. 2019; 15: 1021–34.

  20. 20.

    Office for National Statistics. https://www.ons.gov.uk/. Accessed 12 Sep 2019.

  21. 21.

    Yu B, Tiwari RC. Application of EM algorithm to mixture cure model for grouped relative survival data. J Data Sci. 2007; 5: 41–51.

  22. 22.

    Poehl J, Felizzi F (2018) felizzi/Cure_models: Cure_models_tutorial (Version v1.0). Zenodo. https://doi.org/10.5281/zenodo.1405892.

  23. 23.

    Felizzi F, Paracha N, Pöhlmann J, et al. Mixture cure models in oncology: a tutorial and practical guidance. PharmacoEconomics Open. 2021. https://doi.org/10.1007/s41669-021-00260-z.

  24. 24.

    NICE Final Appraisal Document. Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma. August 2020. https://www.nice.org.uk/guidance/ta649/documents/final-appraisal-determination-document.

  25. 25.

    Howlader N, Mariotto AB, Besson C, et al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer. 2017; 123 (17): 3326–34.

  26. 26.

    NICE Final Appraisal Document. Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. January 2019. https://www.nice.org.uk/guidance/ta567/documents/final-appraisal-determination-document.

  27. 27.

    Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019; 6(5): e254–65.

  28. 28.

    NICE Single Technology Appraisal 2019. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies [ID1115] Committee Papers. https://www.nice.org.uk/guidance/ta559/evidence/appraisal-consultation-committee-papers-pdf-6661404973. Accessed 21 Aug 2020.

  29. 29.

    Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380: 45–56.

  30. 30.

    Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019; 20 (1): 31–42.

  31. 31.

    Ouwens MJNM, Mukhopadhyay P, Zhang Y, et al. Estimating lifetime benefits associated with immune-oncology therapies: challenges and approaches for overall survival extrapolations. Pharmacoeconomics. 2019; 37: 1129–38.

  32. 32.

    Betts KA, Thuresson PO, Du EX, et al. Is polatuzumab vedotin plus bendamustine-rituximab cost-effective for patients in the United States with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma? Presented at ISPOR Europe 2019 Annual Meeting, 2–6 November 2019, Copenhagen, Denmark. Poster PCN238.

The original article has been corrected.